Russell Frank Company’s Regeneron Pharmaceuticals REGN Stock Holding History

Russell Frank Company’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$74.2M	Buy	205,814 +88,047	+75%	+$36.3M	0.13%	178
2015 Q4	$64.6M	Buy	117,767 +20,505	+21%	+$11.1M	0.11%	208
2015 Q3	$45.2M	Buy	97,262 +7,473	+8%	+$4.01M	0.08%	257
2015 Q2	$45.8M	Buy	89,789 +21,312	+31%	+$10.4M	0.07%	300
2015 Q1	$30.9M	Buy	68,477 +3,255	+5%	+$1.38M	0.06%	386
2014 Q4	$26.6M	Sell	65,222 -23,317	-26%	-$9.17M	0.05%	454
2014 Q3	$31.9M	Sell	88,539 -19,229	-18%	-$6.44M	0.06%	367
2014 Q2	$33.5M	Sell	107,768 -51,776	-32%	-$15.3M	0.06%	365
2014 Q1	$47.9M	Buy	159,544 +43,885	+38%	+$13.5M	0.08%	275
2013 Q4	$32.2M	Sell	115,659 -87,920	-43%	-$25.3M	0.06%	363
2013 Q3	$63.7M	Sell	203,579 -7,744	-4%	-$2.04M	0.11%	209
2013 Q2	$52M	Buy	+211,323	New	+$49.2M	0.1%	251

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Russell Frank Company's REGN Position: Q1 2016 in Review

Russell Frank Company increased its Regeneron Pharmaceuticals (REGN) stake by 75% in Q1 2016, buying an estimated $36.3M and bringing the position to 205,814 shares worth $74.2M. The position accounts for 0.13% of the portfolio, ranked #178.

Russell Frank Company first reported a position in REGN in Q2 2013 and has held it in 12 quarters since. 549 funds tracked by Wall St. Rank hold REGN as of Q1 2016.

Russell Frank Company held 205,814 shares of Regeneron Pharmaceuticals worth $74.2M as of Q1 2016.
Russell Frank Company bought 88,047 Regeneron Pharmaceuticals shares in Q1 2016, an estimated $36.3M.
Regeneron Pharmaceuticals made up 0.13% of Russell Frank Company's portfolio in Q1 2016, its #178 holding.
Russell Frank Company first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 12 quarters since.
549 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.